Astaxanthin mitigates doxorubicin-induced cardiotoxicity via inhibiting ferroptosis and autophagy: a study based on bioinformatic analysis and in vivo/vitro experiments
BackgroundDoxorubicin (DOX), a widely employed chemotherapeutic agent in cancer treatment, has seen restricted use in recent years owing to its associated cardiotoxicity. Current reports indicate that doxorubicin-induced cardiotoxicity (DIC) is a complex phenomenon involving various modes of cell de...
Saved in:
| Main Authors: | Bowen Yin, Jingyi Ren, Xuanyi Liu, Yadong Zhang, Jinshi Zuo, Rui Wen, Huanting Pei, Miaomiao Lu, Siqi Zhu, Zhenao Zhang, Ziyi Wang, Yanyi Zhai, Yuxia Ma |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1524448/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al. -
Investigate if Metoprolol and Troxerutin Could Prevent Cardiotoxicity Mitigated by Doxorubicin
by: Fouad Zeidan Hamzah, et al.
Published: (2025-07-01) -
Pathophysiology of Doxorubicin-Mediated Cardiotoxicity
by: Roberto Arrigoni, et al.
Published: (2025-04-01) -
Bioinformatics analysis of ferroptosis-related biomarkers and potential drug predictions in doxorubicin-induced cardiotoxicity
by: Jian Yu, et al.
Published: (2025-04-01) -
The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)